- Home
- LICN vs ABVC Comparison
LICN vs ABVC Comparison
Compare LICN & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- ABVC
- Stock Information
- Founded
- LICN 2004
- ABVC 2015
- Country
- LICN China
- ABVC United States
- Employees
- LICN N/A
- ABVC N/A
- Industry
- LICN
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- ABVC Health Care
- Exchange
- LICN Nasdaq
- ABVC Nasdaq
- Market Cap
- LICN 8.7M
- ABVC 9.9M
- IPO Year
- LICN 2023
- ABVC N/A
- Fundamental
- Price
- LICN $0.07
- ABVC $0.70
- Analyst Decision
- LICN
- ABVC
- Analyst Count
- LICN 0
- ABVC 0
- Target Price
- LICN N/A
- ABVC N/A
- AVG Volume (30 Days)
- LICN 30.4M
- ABVC 1.2M
- Earning Date
- LICN 12-31-2024
- ABVC 03-12-2025
- Dividend Yield
- LICN N/A
- ABVC N/A
- EPS Growth
- LICN 36.90
- ABVC N/A
- EPS
- LICN 0.28
- ABVC N/A
- Revenue
- LICN $41,929,000.00
- ABVC $509,788.00
- Revenue This Year
- LICN N/A
- ABVC N/A
- Revenue Next Year
- LICN N/A
- ABVC N/A
- P/E Ratio
- LICN $0.28
- ABVC N/A
- Revenue Growth
- LICN 24.86
- ABVC N/A
- 52 Week Low
- LICN $0.06
- ABVC $0.40
- 52 Week High
- LICN $2.44
- ABVC $1.73
- Technical
- Relative Strength Index (RSI)
- LICN 29.78
- ABVC 75.66
- Support Level
- LICN $0.06
- ABVC $0.40
- Resistance Level
- LICN $0.08
- ABVC $0.88
- Average True Range (ATR)
- LICN 0.01
- ABVC 0.08
- MACD
- LICN 0.02
- ABVC 0.02
- Stochastic Oscillator
- LICN 56.39
- ABVC 62.42
About LICN Lichen China Limited
Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.